Literature DB >> 16013445

Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells.

Ahmad Shariftabrizi1, Mohammad Reza Khorramizadeh, Farshid Saadat, Kamran Alimoghadam, Farnaz Safavifar, Mohammad Reza Ebrahimkhani.   

Abstract

BACKGROUND: The level of activity of the telomerase has been shown to correlate with the degree of invasiveness in several tumor types. In addition, cellular redox state is believed to regulate the secretion of matrix metalloproteinase-2 (MMP-2). AIMS: To determine the effect of anti-sense telomerase treatment of prostate cancer cells on MMP-2 activity, and the reactive oxygen and nitrogen species (two effectors of cellular redox state).
METHODS: Anti-sense oligonucleotide against RNA component of human telomerase (hTR) was introduced into the cells using Fugene-6 transfection reagent. The activity of telomerase was assessed using Telomere Repeat Amplification Protocol (TRAP assay). Activity of matrix metalloproteinase-2 (MMP-2) was determined by zymography. Levels of intracellular reactive oxygen species (ROS) and nitric oxide metabolites were measured by dichlorofluorescein diacetate (DCFH-DA) staining and Griess reagent, respectively. The level of apoptosis was determined using TUNEL assay.
RESULTS: TRAP assay showed more than 90% inhibition of telomerase activity after 72 h of transfection. Pro-MMP-2 activity was decreased down to 50% of the control levels. Intracellular reactive oxygen species were also significantly decreased. Neither apoptosis rate nor the level of nitric oxide metabolites was significantly different between anti-sense treated and control cells.
CONCLUSIONS: Concomitant reduction of the pro-MMP-2 secretion and ROS in PC-3 cells following hTR inhibition suggests that over-activity of telomerase in cancer cells might increase the level of matrix metalloproteinase-2 and thus, be directly involved in the invasion process through enhancement of intracellular oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16013445     DOI: 10.1007/s11010-005-8158-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  Involvement of 14-3-3 proteins in nuclear localization of telomerase.

Authors:  H Seimiya; H Sawada; Y Muramatsu; M Shimizu; K Ohko; K Yamane; T Tsuruo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

Authors:  G F Greene; Y Kitadai; C A Pettaway; A C von Eschenbach; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 3.  Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets.

Authors:  J Pfeilschifter; W Eberhardt; A Huwiler
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

4.  Telomerase activity and lymphovascular invasion in breast cancer.

Authors:  K M Mokbel; C N Parris; M Ghilchik; C N Amerasinghe; R F Newbold
Journal:  Eur J Surg Oncol       Date:  2000-02       Impact factor: 4.424

5.  Gastric cancer with high telomerase activity shows rapid development and invasiveness.

Authors:  Y Kakeji; Y Maehara; T Koga; K Shibahara; A Kabashima; E Tokunaga; K Sugimachi
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

6.  Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species.

Authors:  Hannah J Zhang; Weiling Zhao; Sujatha Venkataraman; Michael E C Robbins; Garry R Buettner; Kevin C Kregel; Larry W Oberley
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

7.  Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.

Authors:  John W M Martens; Anieta M Sieuwerts; Joan Bolt-deVries; Peter T Bosma; Susan J J Swiggers; Jan G M Klijn; John A Foekens
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

8.  The role of AP-1 in matrix metalloproteinase gene expression.

Authors:  C W Lin; H I Georgescu; C H Evans
Journal:  Agents Actions       Date:  1993

9.  Telomerase activity in human bladder cancer.

Authors:  Y Lin; H Miyamoto; K Fujinami; H Uemura; M Hosaka; Y Iwasaki; Y Kubota
Journal:  Clin Cancer Res       Date:  1996-06       Impact factor: 12.531

10.  Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707.

Authors:  Judith Haendeler; Jörg Hoffmann; Ralf P Brandes; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

View more
  4 in total

1.  Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.

Authors:  Christian Senft; Maike Priester; Margareth Polacin; Katrin Schröder; Volker Seifert; Donat Kögel; Jakob Weissenberger
Journal:  J Neurooncol       Date:  2010-06-30       Impact factor: 4.130

2.  The Repression of Matrix Metalloproteinases and Cytokine Secretion in Glioblastoma by Targeting K+ Channel.

Authors:  Farshid Saadat; Zohreh Zareighane; Farnaz Safavifar; Seyedeh Zohreh Jalali; Azar Berahmeh; Mohammad Reza Khorramizadeh
Journal:  Basic Clin Neurosci       Date:  2021-11-01

3.  The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.

Authors:  Danielle Lejeune; Mohammad Hasanuzzaman; Amanda Pitcock; Joseph Francis; Inder Sehgal
Journal:  Mol Cancer       Date:  2006-06-06       Impact factor: 27.401

4.  Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer.

Authors:  S Xinqiang; Z Mu; C Lei; L Y Mun
Journal:  Clin Transl Sci       Date:  2017-05-23       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.